BioCorRx (OTCQB: BICX) is the owner and creator of an innovative addiction treatment program used by a network of independent treatment centers to improve the lives of their patients struggling with alcohol and opioid addictions. The BioCorRx® Recovery Program leverages an innovative, two-pronged approach that addresses the underlying physical and behavioral issues associated with these addictions. The first half of this approach relies on a highly effective, proprietary implant formulation of the FDA-approved medication naltrexone, for which BioCorRx holds worldwide license rights (excluding Australia and New Zealand). The second half focuses on a modular counseling program coupled with overlapping peer support that is tailored specifically for those afflicted with alcohol and opioid addictions, helping to prepare them both physically and mentally for a life without these often dangerous substances.
America’s opioid epidemic is an increasingly treacherous issue that affects millions of people across the country. Per data from the Centers for Disease Control and Prevention, more than half a million people in the United States died from drug overdose from 2000 to 2015. Of those, more than 60 percent were linked to an opioid. Likewise, deaths from prescription opioids have more than quadrupled since 1999, driven by a nearly identical spike in the amount of prescription opioids sold. The negative implications associated with this addiction include traumatic life events for the addicted and their loved ones, as well as monumental financial expense. A 2010 study conducted by the American Society of Addiction Medicine found that addiction costs an estimated $700 billion annually in the U.S. alone.
Treating this growing problem has proven difficult. In 2011, the Substance Abuse and Mental Health Services Administration reported that 23.5 million persons aged 12 or older, roughly 9.3 percent of the population, needed treatment for an illicit drug or alcohol abuse problem. Of those, only 11.2 percent received the vital treatment at a specialty facility. BioCorRx aims to close this gap by both operating specialty facilities to aid those in need and providing a more thorough treatment program that’s been shown to lower patient drop-out rates, due to reduced cravings, and increase compliance rates, through automatic medication delivery and discreet outpatient treatment options.
In recent months, BioCorRx, through its BioCorRx Pharmaceuticals subsidiary, has looked to continue building on this proven medication through the clinical development of BICX101, a sustained release, injectable naltrexone for the treatment of opioid and alcohol use disorders. In early April, the company announced that three different formulations of the drug candidate showed success in reaching 28 days of sustained release in its preclinical studies, including one with an injection volume of just one milliliter. Following this result, BioCorRx formally requested a pre-IND meeting with the U.S. Food and Drug Administration as it continues to conduct additional studies in order to compile more data points.
In a business update issued earlier this month, Lourdes Felix, CFO, COO and director of BioCorRx, noted the strength of the company’s balance sheet following a March equity financing of $940,000 with accredited investors, as well as an investment of $1.7 million from Alpine Creek Capital Partners. Capital stemming from these transactions is expected to allow BioCorRx to continue executing on its business plan, including completion of “a few rounds of preclinical studies of BICX101” and accelerated sales and marketing activities related to its BioCorRx Recovery Program.
A strong balance sheet isn’t the only aspect of BioCorRx’s growth strategy about which prospective shareholders should be particularly optimistic. On May 16, the company announced its submission of a listing application for the Nasdaq Capital markets. The move comes less than two months after OTC Markets Group (OTCQX: OTCM) welcomed BioCorRx to the OTCQB Venture Market, which it reserves for early-stage and developing companies that are current in their reporting and undergo an annual verification and management certification process. The company will be required to meet a number of Nasdaq listing requirements in order to complete the uplist, but CFO Felix noted that members of BioCorRx’s management team “look forward to the prospect of a NASDAQ listing,” which they anticipate will “enhance BioCorRx’s visibility in the investment community to a larger market and provide for a broader, more diverse base of shareholders.”
Addressing the growing opioid epidemic in the United States, as well as lingering alcohol addiction issues, represents both an urgent call to action and a sizable market opportunity for companies offering proven effective treatment options. BioCorRx, through its innovative non-addictive medication-assisted treatment (MAT) program and promising clinical pipeline, represents an opportunity for the investment community to participate in the resolution of this crisis while capitalizing on the growth prospects of a leading edge health care solutions company.
For more information, visit www.BioCorRx.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
No comments:
Post a Comment